Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Neoplasms 3Breast Neoplasms 2Anorexia 2Vomiting 1Neoplasms, Second Primary 1Mesothelioma, Malignant 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Cachexia 1

Interventions

Cisplatin 4tremelimumab 3Pemetrexed 3durvalumab 2atezolizumab 2Radiotherapy 2Nivolumab 2Mitomycin 2Doxorubicin 2toripalimab 1talazoparib 1rucaparib 1regorafenib 1ranpirnase 1pembrolizumab 1niraparib 1liposomal doxorubicin 1dostarlimab 1cemiplimab 1bemcentinib 1avelumab 1abemaciclib 1Vinorelbine 1Vinblastine 1Thiostrepton 1Surgical Procedures, Operative 1Oxaliplatin 1One-Lung Ventilation 1Neoadjuvant Therapy 1Megestrol Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Mesothelioma, Malignant × Megestrol Acetate × Clear all
NCT00002465 2013-11-06

High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma

National Cancer Institute (NCI)

Phase 1/2 Unknown
BreastGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡